Global Heart Transplant Market 2025-2035

Description

List of Tables

Global Heart Transplant Market Size, Share & Trends Analysis by Surgery Type (Total Artificial Heart, Ventricular Assist Devices, and Others) and by End User (Hospitals, Cardiac Institutes, and Others) Forecast Period (2025-2035)

Industry Overview

Heart transplant market was valued at $12.3 billion in 2024 and is projected to reach $35.2 billion by 2035, growing at a CAGR of 10.1% during the forecast period (2025-2035). The market is growing due to the increasing prevalence of cardiovascular diseases and heart failure, especially in the aging population. Key drivers include advancements in surgical techniques, the need for life-saving interventions, and government support for research. Challenges include the shortage of donor organs and skilled surgeons, high treatment costs, and issues like immunosuppressant drug side effects. Opportunities lie in emerging technologies like regenerative medicine, xenotransplantation, and mechanical assist devices.

Market Dynamics

Rising Burden of Heart Failure and Donor Utilization Improvements

The growing prevalence of advanced heart failure globally increases candidate pools for transplant; simultaneously, technologies that improve donor heart assessment and preservation (ex-vivo perfusion, extended-criteria donor protocols) raise transplantable organ supply and throughput, directly expanding market demand for preservation systems and associated services.

Technological Innovation in Devices and Post-Transplant Care

Advances in mechanical circulatory support (durable VADs, total artificial hearts) and better immunosuppressive regimens reduce mortality and extend waiting-list options, creating a closer integration between device and transplant markets. Innovation drives capital spending by transplant centers and increases recurrent revenues for therapeutics and monitoring services.

Regulatory & Reimbursement Environment plus Center Capacity

Favorable reimbursement policies, expanded transplant center capabilities, and streamlined regulatory approvals for organ-preservation devices increase procedure volumes. Conversely, reimbursement uncertainty or capacity constraints (ICU beds, trained teams) can bottleneck growth, so policy and healthcare infrastructure remain determining factors for regional market trajectories.

Market Segmentation

Based on the surgery type, the market is segmented into total artificial heart, ventricular assist devices, and others.
Based on the end user, the market is segmented into hospitals, cardiac institutes, and others.

Ventricular Assist Devices Segment to Grow at a Considerable Market Share

Among all segments, Ventricular Assist Devices (VADs) are expected to hold the largest share in the Global Heart Transplant Market during the forecast period. The dominance of the ventricular assist devices segment is driven by their increasing adoption as a life-saving solution for patients with end-stage heart failure awaiting transplantation, as well as for those ineligible for transplant procedures. VADs serve as both a bridge-to-transplant and destination therapy, significantly improving patient survival rates and quality of life. The continuous technological advancements in device designs, such as miniaturization, improved biocompatibility, and enhanced battery life, have contributed to their wider acceptance across healthcare institutions globally. Moreover, the rising prevalence of chronic cardiovascular diseases, the growing geriatric population, and the shortage of donor hearts further fuel the demand for these devices. Leading medical centers are increasingly integrating VAD therapy into advanced heart failure management programs, supported by favorable reimbursement policies and clinical success rates.

Hospitals: A Key Segment in Market Growth

Hospitals represent the key segment driving growth in the global heart transplant market. They hold the largest share due to their advanced infrastructure, availability of skilled professionals, and capacity to manage complex transplant procedures. Hospitals serve as the central hub for heart transplant surgeries, post-operative care, and adoption of advanced technologies such as organ preservation systems and immunosuppressive therapies. The rising prevalence of heart failure, an aging global population, and increased access to specialized transplant centers further fuel this segment's growth. While cardiac institutes and other facilities play supportive roles, hospitals remain the dominant and fastest-growing end-user segment, contributing most significantly to overall market expansion.

Regional Outlook

The global heart transplant market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global heart transplant market, accounting for the largest share of procedures, infrastructure, and commercial activity in this field, a position supported by both clinical activity and market analyses. Clinically, the U.S. performs more heart transplants than any other single nation: recent registry and national data show the country surpassed 4,000 adult heart transplants in 2023, and overall organ transplantation volumes in the U.S. reached record levels (over 48,000 organ transplants reported in 2024), underlining the scale and maturity of its transplant ecosystem.

Economically and commercially, market research firms and sector reports consistently identify North America, led by the US, as the dominant region for the transplantation market, attributing this to a combination of high healthcare spending, reimbursement systems that support complex procedures, advanced hospital networks, and ongoing investment in transplant technologies and therapeutics. Several structural factors explain why the U.S. leads: a dense concentration of high-volume transplant centers and specialized cardiac units (some U.S. centers set new institutional records for annual transplant volume), robust organ procurement and distribution networks, and widespread availability of advanced bridging devices such as ventricular assist devices and ex vivo organ preservation technologies that expand the donor pool and increase transplant feasibility.

In addition, the American regulatory, reimbursement, and research environment propels commercial activity, pharmaceutical, device, and biologic companies develop and trial new immunosuppressants, preservation solutions, and diagnostics in the U.S. first, which concentrates R&D spending and market uptake. Public and private funding, coupled with relatively favorable reimbursement for complex cardiac care, drives adoption of innovations and supports higher procedure volumes versus lower-income countries, where access remains constrained. Finally, international registries and comparative reports repeatedly show a strong correlation between GDP per capita and heart transplant rates, which explains why affluent health systems like the U.S. dominate the market: they combine clinical capability, donor infrastructure, financing, and innovation ecosystems that together translate into the largest share of heart transplants and associated market revenues worldwide.

Market Players Outlook

The major companies operating in the global heart transplant market include Abbott Laboratories, Boston Scientific, Medtronic, Novartis, Pfizer, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

In August 2025, AIIMS Jodhpur planned to launch a heart transplant program, enhancing cardiac care and transplant capabilities in the region. The heart was retrieved from Anita, transported to Jaipur through a coordinated effort.

The Report Covers:

Market value data analysis for 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global heart transplant market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2024069

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Heart Transplant Market Sales Analysis - Heart Transplant | End User ($ Million)
Heart Transplant Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Heart Transplant Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Heart Transplant Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Heart Transplant Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Heart Transplant Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Heart Transplant Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Heart Transplant Market Revenue and Share by Manufacturers
Heart Transplant Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Boston Scientific
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Medtronic PLc
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Novartis
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Pfizer Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Heart Transplant Market Sales Analysis by Heart Transplant ($ Million)

5.1. Total Artificial Heart
5.2. Ventricular Assist Devices
5.3. Others (Heart Restraint Devices)

6. Global Heart Transplant Market Sales Analysis by End User ($ Million)

6.1. Hospitals
6.2. Cardiac Institutes
6.3. Others

7. Regional Analysis

7.1. North American Heart Transplant Market Sales Analysis - Heart Transplant | End User | Country ($ Million)
Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
7.2. European Heart Transplant Market Sales Analysis - Heart Transplant | End User | Country ($ Million)
Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
7.3. Asia-Pacific Heart Transplant Market Sales Analysis - Heart Transplant | End User | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
7.4. Rest of the World Heart Transplant Market Sales Analysis - Heart Transplant | End User | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa

8. Company Profiles

8.1. Abbott Laboratories
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. Abiomed, Inc.
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Apaxis Medical, Inc.
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Berlin Heart GmbH
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. Boston Scientific Corp.
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Bristol-Myers Squibb Co.
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. Calon Cardio-Technology Ltd.
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Carmat S.A.
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. CSL Behring
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. Edwards Lifesciences Corp.
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Jarvik Heart, Inc.
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Johnson & Johnson
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Medtronic plc
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. Novartis AG
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Optum, Inc.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Sanofi S.A.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. SynCardia Systems, LLC
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Terumo Cardiovascular Systems Corp.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Terumo Corp.
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Zimmer Biomet Holdings, Inc.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies